Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | CRHBP | P24387 | 1/20 | 0.57 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.57 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.56 |
| ▸ | THRB | P10828 | 4/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | RECQL | P46063 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.54 |
| ▸ | FEN1 | P39748 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | CASP1 | P29466 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30683369 | 1.00 | ALDH1A1 (0.61) | ALDH1A1MAPK1HIF1ALMNACRHBP | |
| SCHEMBL11449629 | 0.95 | ALDH1A1 (0.59) | ALDH1A1MAPK1HIF1ALMNACRHBP | |
| SCHEMBL2125979 | 0.89 | ALDH1A1 (0.65) | ALDH1A1MAPK1HIF1ALMNACRHBP | |
| SCHEMBL10792071 | 0.84 | ALDH1A1 (0.62) | ALDH1A1MAPK1HIF1ALMNATHRB | |
| SCHEMBL16372242 | 0.84 | ALDH1A1 (0.68) | ALDH1A1MAPK1HIF1ALMNACRHBP | |
| SCHEMBL13346899 | 0.84 | ALDH1A1 (0.62) | ALDH1A1MAPK1HIF1ATHRBPOLB | |
| SCHEMBL17690580 | 0.83 | CHRM2 (0.48) | ALDH1A1MAPK1HIF1ALMNACRHBP | |
| SCHEMBL11278113 | 0.83 | ALDH1A1 (0.61) | ALDH1A1MAPK1HIF1ATHRBPOLB | |
| SCHEMBL31029939 | 0.83 | ALDH1A1 (0.66) | ALDH1A1MAPK1HIF1ALMNACRHBP | |
| SCHEMBL14443210 | 0.82 | MAPT (0.62) | ALDH1A1MAPK1HIF1ALMNACRHBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117258329-A | Method for preparing chiral hexaconazole | 江西鑫臻科技有限公司 | 2023-12-22 | — | — | CN | disclosed |
| CN-101805300-B | Method for preparing chiral hexaconazole | BEIJING OKEANOS TECH CO., LTD. (CN) | 2012-02-15 | — | — | CN | disclosed |
| US-7994203-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-08-09 | — | — | US | disclosed |
| US-7994203-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-08-09 | — | — | US | disclosed |
| US-7994203-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-08-09 | — | — | US | disclosed |
| EP-2328902-A1 | PYRAZOLO [5,1-B]OXAZOLE DERIVATIVES AS CRF1 ANTAGONISTS | Novartis AG (CH) | 2011-06-08 | — | — | EP | disclosed |
| CN-101805300-A | Method for preparing chiral hexaconazole | OKEANOS TECH CO LTD | 2010-08-18 | — | — | CN | disclosed |
| WO-2010015628-A1 | PYRAZOLO [5,1-B] OXAZOLE DERIVATIVES AS CRF1 ANTAGONISTS | NOVARTIS AG (CH) | 2010-02-11 | — | — | WO | disclosed |
| WO-2010015628-A1 | PYRAZOLO [5,1-B] OXAZOLE DERIVATIVES AS CRF1 ANTAGONISTS | NOVARTIS AG (CH) | 2010-02-11 | — | — | WO | disclosed |
| US-20100035874-A1 | Organic compounds | NOVARTIS AG (CH) | 2010-02-11 | — | — | US | disclosed |
| US-20100035874-A1 | Organic compounds | NOVARTIS AG (CH) | 2010-02-11 | — | — | US | disclosed |
| US-20100035874-A1 | Organic compounds | NOVARTIS AG (CH) | 2010-02-11 | — | — | US | disclosed |
| EP-0636120-B1 | EPOXIDATION PROCESS OF CARBONYL COMPOUNDS USING SULPHONIUM OR SULPHOXONIUM YLIDES AND INTERMEDIATES | ZENECA LTD (GB) | 1999-09-08 | — | — | EP | disclosed |
| US-5750740-A | Process for preparing epoxides from carbonyl compounds using sulphonium or sulphoxonium ylides and intermediates useful therein | ZENECA LIMITED (GB) | 1998-05-12 | — | — | US | disclosed |
| US-5637727-A | Process for preparing epoxides from carbonyl compounds using sulphonium or sulphoxonium ylides and intermediates useful therein | ZENECA LIMITED (GB) | 1997-06-10 | — | — | US | disclosed |
| EP-0636120-A1 | EPOXIDATION PROCESS OF CARBONYL COMPOUNDS USING SULPHONIUM OR SULPHOXONIUM YLIDES AND INTERMEDIATES | ZENECA LIMITED (GB) | 1995-02-01 | — | — | EP | disclosed |
| WO-1992014703-A1 | EPOXIDATION PROCESS OF CARBONYL COMPOUNDS USING SULPHONIUM OR SULPHOXONIUM YLIDES AND INTERMEDIATES | ZENECA LIMITED (GB) | 1992-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035874-A1 | Organic compounds | CRH, CRHR1, CRHR2 | ALDH1A1 1728/4885MAPK1 913/4885HIF1A 742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.